Stocktoria
AMARIN CORP PLCUK AMRN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1993-04-01
AMARIN CORP PLCUK financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $213.6M | $228.6M | $306.9M | $369.2M | $583.2M |
| Gross profit | $120.9M | $81.4M | $165.5M | $242.5M | $461.9M |
| R&D expense | $19.8M | $20.9M | $22.2M | $30.4M | $29.3M |
| SG&A expense | $115.0M | $152.3M | $199.9M | $304.4M | $408.3M |
| Operating income | -$50.2M | -$91.8M | -$67.6M | -$105.9M | $10.5M |
| Interest expense | $7,000 | $7,000 | $8,000 | $15,000 | $129,000 |
| Income tax | $2.8M | $5.0M | $5.4M | $2.0M | $3.6M |
| Net income | -$38.8M | -$82.2M | -$59.1M | -$105.8M | $7.7M |
| EPS (diluted) | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 |
| Operating cash flow | $6.7M | -$31.0M | $6.9M | -$180.1M | -$66.5M |
| Cash & equivalents | $134.7M | $121.0M | $199.3M | $217.7M | $219.5M |
| Inventory | $195.9M | $166.0M | $258.6M | $228.7M | $234.7M |
| Total assets | $670.8M | $685.3M | $831.7M | $886.2M | $1.1B |
| Total liabilities | $211.5M | $199.2M | $279.6M | $290.8M | $401.0M |
| Shareholders' equity | $459.3M | $486.2M | $552.1M | $595.3M | $667.1M |
Source: SEC EDGAR filings · CIK 0000897448 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.